Loading
companiesCompany
IDEAYA Biosciences
IDEAYA Biosciences develops cancer drugs matched to the genetic make-up of a patient's tumour. Its most advanced drug, darovasertib, is in late-stage trials for a rare eye cancer called uveal melanoma.
Overview
IDEAYA Biosciences is a South San Francisco precision oncology company working on synthetic lethality, metabolic and epigenetic tumour dependencies. Its lead programme, darovasertib (a PKC inhibitor), is in phase 3 registrational trials in metastatic uveal melanoma and, with crizotinib, as adjuvant therapy in primary uveal melanoma (the OptimUM-11 trial with Servier dosed its first patient in September 2026), plus phase 2 studies in GNAQ/11-mutant tumours. Other programmes include IDE849, a DLL3-directed topoisomerase 1 antibody-drug conjugate in phase 1/2 for small cell lung cancer, for which the company reported FDA agreement on a phase 3 design in August 2026; IDE034 (B7H3/PTK7 ADC); IDE161 (PARG inhibitor); IDE397 (MAT2A inhibitor, phase 2) and IDE892 (PRMT5) for MTAP-deleted cancers; and IDE574 (KAT6/7). IDEAYA listed on Nasdaq in May 2019, raising 57.5 million US dollars gross in its IPO.
Headquarters
South San Francisco, CA, US
Scorecard
All companies#375of 1244 companies, score 10
- phase 3 +3
- modalities +2
- registry trials +5
0 approved, 1 in phase 3, 0 earlier, 0 targets, 6 registry studies. Formula on the scorecards page.
Funding
All startupsPublic
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| IPO · 5.75 million shares at 10 US dollars, including full exercise of the underwriters' option | 2019 | $58M | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Biotech · IDYA
Stage
Public
Website
Phase 3small molecule
Darovasertib is an experimental small-molecule drug from IDEAYA Biosciences in phase 3 trials for uveal melanoma and melanoma, with its target not yet stated publicly.
Notes
top- Later follow-on offerings and the GSK partnership were not sourced. Founding year not sourced. Pancreatic cancer tag rests on an August 2026 news headline about a Genentech clinical collaboration in MTAP-deleted KRAS G12D pancreatic cancer.
Similar pages
- TargetGNAQ
Shares Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions, Darovasertib, Melanoma.
- CancerUveal melanoma
Shares Neoadjuvant Darovasertib in Primary Uveal Melanoma, Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma, (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma, Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions.
- TargetGNA11
Shares Darovasertib, Melanoma.
- TrialAdaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Shares DLL3, Small-cell lung cancer.
- TrialAdaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Shares DLL3, Small-cell lung cancer.
- TreatmentRovalpituzumab tesirine
Shares DLL3, Antibody-drug conjugate (ADC), Small-cell lung cancer.
- PairingSequencing DLL3 engager and B7-H3 ADC in relapsed SCLC
Shares DLL3, Small-cell lung cancer.
- CompanyHarpoon Therapeutics
Shares DLL3, Small-cell lung cancer.
cancers
fronts
technologies
targets
drugs
Phase 3small molecule
trials
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaA Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung CancerA Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumorsIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaNeoadjuvant Darovasertib in Primary Uveal MelanomaStudy of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal MelanomaStudy of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions